BuyersStrike!

It Was Dark Over Westphalia

Quick Take – What Stupidity Is Cytodyn Finishing Up The Week With? (CYDY)

Just when we thought we could end the week without any more insanity, everyone's favorite reverse-merger pink sheet Coronacrapper, **Cytodyn (CYDY)**, issued a brand new, utterly ridiculous, press release (here (https://finance.yahoo.com/news/cytodyn-seeks-uk-approval-leronlimab-043600686.html)). No doubt desperate to maintain a $4 bid price for that ever-elusive "uplisting" (Pro Tip: any company that talks about **UPlisting is a scam**, plain and simple. **Cytodyn** is currently **UNlisted**, it is applying for an **INITIAL** listing). Let's take a look at what BS **The NaDDir*** is slinging this morning:

CytoDyn Seeks UK Approval of Leronlimab for HIV and COVID-19

Interesting, seeing as though the company couldn't even get its BLA accepted for review in the USA. Exactly what does "seeking approval" entail? Read past the headine:

> *VANCOUVER, Washington, Aug. 06, 2020 (GLOBE NEWSWIRE) — **CytoDyn Inc. (OTC.QB: CYDY)**, ("CytoDyn" or the "Company"), a late-stage biotechnology company, announced today it will submit requests for pre-submission meetings (equivalent to pre-BLA meeting in U.S.) in the U.K. for leronlimab as an HIV treatment in combination with HAART for highly treatment experienced HIV patients (350 mg dose, self-injectable, subcutaneous), as well as for emergency approval of leronlimab for COVID-19 patients with mild-to-moderate symptoms (Phase 2 – CD10).*

In **The NaDDir*'s** world (*spelled thusly for a **double dose** of that sweet sweet stock pimpin') **seeking approval** actually means merely **submitting a request for a meeting**!

And the subject of that meeting is quite interesting, the **350mg dose** of leronlimab for HIV combination therapy. The company submitted the now infamous botched BLA for that same indication in the USA, but for the **700mg dose**. After a series of miscues by **Cytodyn**, the FDA, as you may recall, sent the company a humiliating **RTF** (Refuse To File) letter, telling them to go back to the drawing board.

Any why even bother with the **350mg** dose? By the company's own admission it doesn't work very well, with only a **70%** response rate.

- R5 patients w/suppressed viral load replacing HAART with leronlimab monotherapy
  - **1) One dose (2 consecutive injections), once a week, self administered at home**
  - **2) High responder's rate – non-responders return to their original regimen without any resistance or harm – No ADA (Anti-Drug Antibody) presence – No X4 grow out during the monotherapy**
- **Regulatory path**
  - **Submit pivotal trial to the FDA 2Q2019 – Currently in discussion with the FDA**

Dose	Average duration post 10 weeks	Responder's rate post 10 weeks
350 mg	38 weeks	70%
525 mg	29 weeks	95%
700 mg	19 weeks	88%

Notice anything else about that chart? When the **middle dose outperforms** the low **and** the high dose, what should that tell you?

One last tidbit, **one dose is actually 2 injections**. Good luck with that.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Posted in Bio-Dreck, CoronaCrap, Reverse Mergers on August 7, 2020 by BuyersStrike!. 2 Comments

2 comments

1. **Bluefish** says:
   August 8, 2020 at 9:12 am
   The only coronaturds are people like yourself. Also known as Covidiots. Do you even read, bro?

   REPLY
2. **Jack Crosby** says:
   September 9, 2020 at 4:51 pm
   Holy shit! I just read a few of your so-called articles and I am blown away by the level of grand mal shitheadedness you exhibit with your writing skills. This is beyond embarrassing. Do yourself a HUGE favor and outsource the writing of your pieces. You are NOT doing yourself any favors by being the one behind the keyboard. Wow! Just wow!

   REPLY